In a notable advancement for hemophilia treatment, Pfizer Inc. (NYSE: PFE) has received U.S. Food and Drug Administration approval for BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy aimed at adults suffering from moderate to severe hemophilia B. This...
Health Canada’s Nod to Pfizer’s Gene Therapy Pfizer starts 2024 with the approval of its gene therapy, Beqvez (fidanacogene elaparvovec), by Health Canada. This approval is for adults aged 18 and older with a moderately-severe to severe form of hemophilia B, who do...
